肝病合并肾损伤临床诊治新进展

doi:10.3969/j.issn.1672-5069.2022.06.001

Abstract

Han Tao, Liu Yandi, Hu Jiaxuan. Advances in the management of patients with liver disease with kidney injury[J]. Journal of Practical Hepatology, 2022, 25(6): 761-763.

[1] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003, 124(1): 91-96.
[2] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64(4): 531-537.
[3] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012, 120(4): c179-184.
[4] Angeli P, Garcia-Tsao G, Nadim M, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71(4): 811-822.
[5] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71(1): 156-162.
[6] Sanyal A, Van Natta M, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med, 2021, 385(17): 1559-1569.
[7] Targher G, Byrne C. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol, 2017, 13(5): 297-310.
[8] Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol, 2021, 6(1): 73-79.
[9] Di Sessa A, Guarino S, Melone R, et al. Relationship between nonalcoholic fatty liver disease and chronic kidney disease could start in childhood. World J Gastroenterol, 2021, 27(34): 5793-5795.
[10] Choe A, Ryu D, Kim H, et al. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol, 2020, 21(1): 50.
[11] Heda R, Yazawa M, Shi M, et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol, 2021, 27(17): 1864-1882.
[12] Shah A, Amarapurkar D. Spectrum of hepatitis B and renal involvement. Liver Int, 2018, 38(1): 23-32.
[13] Kayode-Ajala F, Ejikeme C, Picone J, et al. A case of hepatitis C related mixed cryoglobulinemia syndrome. J Community Hosp Intern Med Perspect, 2022, 12(2): 53-56.
[14] Luciano R, Castano E, Moeckel G, et al. Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid. Am J Kidney Dis, 2014, 64(3): 473-476.
[15] Priyaa V, Srinivas B, Gochhait D, et al. Cholemic nephrosis: An autopsy study of a forgotten entity. Turk patoloji dergisi, 2021, 37(3): 212-218.
[16] Heidari R, Mandegani L, Ghanbarinejad V, et al. Mitochondrial dysfunction as a mechanism involved in the pathogenesis of cirrhosis-associated cholemic nephropathy. Biomed Pharmacother, 2019, 109: 271-280.
[17] Kaler B, Karram T, Morgan W, et al. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren Fail, 2004, 26(5): 507-516.
[18] Adiyanti S, Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones, 2012, 44(3): 246-255.
[19] Washburn K, Zappitelli M, Arikan A, et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant, 2008, 23(2): 566-572.
[20] Vaidya V, Ozer J, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol, 2010, 28(5): 478-485.
[21] Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int, 2008, 73(4): 465-472.
[22] Parikh C, Mansour S. Perspective on clinical application of biomarkers in AKI. J Am Soc Nephrol, 2017, 28(6): 1677-1685.
[23] Biggins S, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md), 2021, 74(2): 1014-1048.
[24] Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology, 2021, 162(12):1231-1237.
[25] Fickert P, Rosenkranz A. Cholemic nephropathy reloaded. Semin Liver Dis, 2020, 40(1): 91-100.
[26] Krones E, Eller K, Pollheimer M, et al. Norursodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol, 2017, 67(1): 110-119.

Advances in the management of patients with liver disease with kidney injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Yingying, Ding Huiguo. Current status and challenges of clinical management of cirrhotics with acute kidney injury [J]. Journal of Practical Hepatology, 2022, 25(6): 764-767.
[2]	Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.
[3]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[4]	Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.
[5]	Fan Ye, Zhang Ximei, Zhang Yan. Clinical implication of serum cystatin C, lipoprotein α and nesfatin-1 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 816-819.
[6]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[7]	Xu Chao, Li Lan, Luo Dong, et al.. Construction and application of risk prediction model for nosocomial death in cirrhotics with esophagogastric variceal bleeding after TIPS treatment [J]. Journal of Practical Hepatology, 2022, 25(6): 840-843.
[8]	Lin Xiuhui, Li Nan, Zhang Jiaozhen, et al.. Polymorphisms of PNPLA3 and PRKAA1 genes and their correlation to liver cirrhosis in patients with hepatitis B viral infection [J]. Journal of Practical Hepatology, 2022, 25(6): 844-847.
[9]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[10]	Sun Jing, Zhang Weiwei, Ma Zhiyong, et al.. Prevention of varices re-bleeding in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemie stent and gastric coronary vein embolization [J]. Journal of Practical Hepatology, 2022, 25(6): 853-856.
[11]	Li Xiang, Zhang Tieying, Zhang Xuhui, et al.. Evaluation of esophageal varices by semi-quantitative scoring based on ultrasonography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 857-860.
[12]	Zhang Yaohui, Zheng Zhangzeng, Gao Xing, et al.. Contrast-enhanced ultrasound time-intensity curve in assessment of liver nodules in cirrhotic patients [J]. Journal of Practical Hepatology, 2022, 25(6): 861-864.
[13]	Zhan Zhiyuan, Shen Yang, Wang Fanbing. Short-term hemostatic effect of endoscopic variceal ligation and omeprazole and octreotide combination in the treatment of cirrhotics with first esophageal varices bleeding [J]. Journal of Practical Hepatology, 2022, 25(6): 865-868.
[14]	Shen Yipeng, Zhu Junfeng. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 909-912.
[15]	Nan Yuemin, Li Jiazheng. Liver cirrhosis and infections: the state of the disease [J]. Journal of Practical Hepatology, 2022, 25(5): 609-611.